CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education? Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up Limitations of Repeat Revascularization as an Outcome Measure Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial Significantly less inappropriate shocks in ischemic patients compared to non-ischemic patients: The S-ICD experience of a high volume single-center Potential protective mechanisms of green tea polyphenol EGCG against COVID-19 Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Poor R-wave progression as a predictor of sudden cardiac death in general population and subjects with coronary artery disease

Review Article01 February 2021

JOURNAL:Cardiovasc Drugs Ther. Article Link

Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis

M Biswas, SK Kali. Keywords: stable CAD; CYP2C19 lost of function; MACE

ABSTRACT

PURPOSE - It was aimed to determine the aggregated risk of MACE (major adverse cardiovascular events) in stable CAD patients carrying CYP2C19 LoF alleles taking clopidogrel.


METHODS - Literature was searched in different databases for relevant studies. Aggregated risk was estimated using a fixed/random effect model where p-value<0.05 was considered statistically significant.


RESULTS - In total, 21 studies with 16,194 stable CAD patients were assessed. It was found that patients treated with clopidogrel carrying either one or two CYP2C19 LoF alleles who underwent PCI were associated with significantly increased risk of MACE compared to non-carriers (OR: 1.71, 95% CI: 1.511.94, p<0.00001) that was driven from cardiovascular death (OR: 1.43, 95% CI: 1.021.99, p=0.04), myocardial infarction (OR: 1.75, 95% CI: 1.422.16, p<0.00001), stroke (OR: 2.30, 95% CI: 1.523.47, p<0.0001), and stent thrombosis (OR: 4.08, 95% CI: 2.526.61, p<0.00001). It was also found that carriers of two CYP2C19 LoF alleles were associated with a significantly marked risk of MACE than non-carriers (OR: 2.22, 95% CI: 1.603.09, p<0.00001). Furthermore, the increased risk of MACE remained markedly significant in Asian patients (OR: 2.03, 95% CI: 1.722.40, p<0.00001) and was less significant in western patients (OR: 1.35, 95% CI: 1.111.63, p=0.002). Bleeding events were not significantly different in carriers of CYP2C19 LoF alleles compared to non-carriers (OR: 1.11, 95% CI: 0.851.45, p=0.43).


CONCLUSION - Stable CAD patients treated with clopidogrel and carried CYP2C19 LoF alleles undergoing PCI were associated with significantly increased risk of MACE compared to non-carriers, even markedly significant for Asian patients.